Fractionated Radioactive Cu-ATSM Dosing for Tumor Toxicity Limits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments with radioactive Cu-ATSM for glioblastoma face dose limitations due to body weight loss and hematotoxicity, and therapeutic effects are insufficient.
Innovation Solution
A technique involving multiple administrations of a radioactive dithiosemicarbazone-copper complex at low doses, determined by hematological parameters to avoid dose-limiting toxicity, is employed to enhance antitumor effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a therapeutically effective dose of radioactive Cu-ATSM is administered, then the antitumor effect is improved, but body weight loss and hematotoxicity occur
Solution Approach 1:
The patent applies segmentation by dividing a single high-dose administration into multiple low-dose administrations. This fractional dosing strategy allows the total therapeutic dose to be delivered while distributing the toxic effects across multiple time points, enabling recovery between doses and avoiding the dose-limiting toxicity of single high-dose administration
Solution Approach 2:
The patent implements periodic action through repeated administrations at specific time intervals (e.g., every 72 hours). This periodic dosing schedule maintains continuous antitumor pressure on the tumor while allowing normal tissues to recover from radiation damage between doses, thereby improving the therapeutic ratio
2Object-affected harmful factors
If multiple administration at low dose is performed, then toxicity is reduced, but the therapeutic effect may be insufficient
Solution Approach 1:
The patent applies continuity of useful action by delivering multiple doses over an extended period rather than a single dose. This continuous exposure to radiation maintains persistent damage to tumor cells and their repopulation capacity, ensuring that the cumulative therapeutic effect is sufficient even though each individual dose is low
Solution Approach 2:
The patent employs preliminary action by administering multiple low doses that progressively damage tumor vasculature and create a hypoxic environment before delivering subsequent doses. This preliminary damage to the tumor microenvironment enhances the effectiveness of later administrations by improving drug delivery and increasing tumor cell sensitivity to radiation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach maintains continuous antitumor efficacy while minimizing toxicity, effectively inhibiting tumor growth and extending survival without significant side effects.
Implementation Method 1
radioactive dithiosemicarbazone-copper complex
Implementation Method 2
radioactive dose that avoids dose-limiting toxicity
Data Source
AI summary
This radioactive antitumor agent comprises a radioactive dithiosemicarbazone-copper complex as an active ingredient, and is characterized by being used in such a way that the radioactive dithiosemicarbazone-copper complex is administered multiple times to an organism requiring tumor treatment, at a radioactive dose that avoids dose-limiting toxicity, as determined on the basis of hematological parameters. The multiple administration preferably consists of intermittent administration at time intervals allowing the hematological parameters to return to a normal range.